Results 111 to 120 of about 25,819 (299)

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*

, 2012
Sebastian Rehberg, Perenlei Enkhbaatar, Janina Rehberg, Erin La, Nicky Ferdyan, Steve Qi, Kazimierz Wiśniewski, Lillian D. Traber, Claudio D. Schteingart, Pierre Rivière, Régent Laporte, Daniel L. Traber   +11 more
openalex   +2 more sources

The Oxytocin Receptor in Spermatozoa May Originate From Both Spermatogenesis and Epididymal Maturation, and Regulates Capacitation

Andrology, EarlyView.
Abstract Background The oxytocin receptor (OR) is a G‐protein‐coupled receptor recently identified in human spermatozoa, whose origin and role in sperm physiology remain unknown. Objectives In this study, using the pig as a model, we examine the presence of the OR in ejaculated spermatozoa through immunofluorescence and immunoblotting, and investigate ...
Jesús Martínez‐Hernández, Ferran Garriga, Adeel Ahmad, Lorena Padilla, Carolina Maside, Sergi Bonet, Isabel Barranco, Jordi Roca, Luis Miguel Pastor, Marc Yeste   +9 more
wiley   +1 more source

Hypercalcemia Selectively Decreases Rat Inner Medullary Collecting Duct(IMCD) Vasopressin (AVP)-Elicited Water Permeability (Pf) and Aquaporin-2 (AQP-2) Water Channel Protein Content While Increasing Its Urea Permeability (Purea) and the UT-2 Urea Channel Protein Content • 1650 [PDF]

, 1997
Francisco X. Flores, Akihiko Kato, Michelle A. Baum, Edward M. Brown, Steven Hébert, Jeff M. Sands, H. William Harris   +6 more
openalex   +1 more source

Differential Impact of Polymyxin B Hemadsorption on Long‐Term Mortality in Septic Shock: A Retrospective Analysis of Intra‐Abdominal Versus Extra‐Abdominal Infections

Artificial Organs, EarlyView.
In this single‐center retrospective cohort study, the use of PMX‐HA was significantly associated with a reduced risk of 1‐year mortality in patients with septic shock due to intra‐abdominal infection. In contrast, no significant association was observed between PMX‐HA use and 1‐year mortality risk in patients with septic shock caused by extra‐abdominal
Tomoki Tanaka, Kazunori Fujino, Yasuyuki Tsujita, Yugo Matsumoto, Mitsuhiro Fujino, Hidemitsu Miyatake, Naoto Mizumura, Junji Shimizu, Takuma Kishimoto, Naoto Shiomi   +9 more
wiley   +1 more source

ELECTROPHORETIC STUDIES OF OXYTOCIN AND VASOPRESSIN

, 1953
Sterling P. Taylor, Vincent du Vigneaud, Henry G. Kunkel   +2 more
openalex   +1 more source

Leu8 and Pro8 oxytocin agonism differs across human, macaque, and marmoset vasopressin 1a receptors [PDF]

, 2019
Oxytocin (OXT) is an important neuromodulator of social behaviors via activation of both oxytocin receptors (OXTR) and vasopressin (AVP) 1a receptors (AVPR1a).
French, Jeffrey A., Mustoe, Aaryn, Schulte, Nancy A., Taylor, Jack H., Toews, Myron L.   +4 more
core   +1 more source

Love (Drugs), Happiness, and Morality

Bioethics, EarlyView.
ABSTRACT Various authors, including myself, have argued that happiness and morality operate in a circularly supportive relationship. In this paper, love will be added to this relationship. The new triple correlation will be explored through the following lens: not only do love and happiness reinforce moral action, but they appear to be in a triple ...
Vojin Rakić
wiley   +1 more source

Corticotropin-releasing activity of lysine vasopressin [PDF]

, 1961
Weber, Evelyn Joyce
core   +3 more sources

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Brain Pathology, EarlyView.
The efficacy of the novel anti‐tau active immunotherapy, p5555kb, was tested using two mouse models of tau pathology. p5555kb inoculation increased the survival rate and reduced tau pathology in tau‐overexpressing P301L mice and decreased tau seeding in the brains of C57BL/6 mice injected with human‐purified Alzheimer's disease tau.
Christopher M. Brown, Jeanne K. Brooks, Louise Kelly, Madeline M. Vroom, Matthew Longo, Jean‐Cosme Dodart, Roxana Carare, Justin D. Boyd   +7 more
wiley   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source